Kenmotsu H, et al. – In this study, the survival of patients with non-small cell lung cancer (NSCLC) who received postoperative adjuvant chemotherapy comprising CDDP + vinorelbine (VNR), had been computed. As compared with previous survival data of adjuvant chemotherapy for NSCLC, this study provided evidence for possible improvement of the prognosis after surgical resection of NSCLC and adjuvant chemotherapy comprising CDDP + VNR.

Methods

• Patients with NSCLC who received adjuvant chemotherapy comprising CDDP + VNR at the Shizuoka Cancer Center between February 2006 and October 2011, were retrospectively evaluated.

Results

• This study incorporated one hundred patients who underwent surgical resection of NSCLC.
• Following were the patients’ characteristics: median age 63 years (range 36–74 years), female 34%, never-smokers 20%, and non-squamous NSCLC 73%.
• Pathological stages IIA, IIB, and IIIA were observed in 31, 22, and 47% of patients, respectively.
• 73 and 93% were the 5- and 2-year overall survival rates.
• In addition, the 5- and 2-year relapse-free survival rates were 53 and 62%, respectively.
• Univariate analysis of prognostic factors found no association between patient characteristics (sex, histology, and pathological stage) as well as CDDP dose intensity and survival.
• The 5-year survival rate after recurrence was 29%, and the median survival time after recurrence was 37 months, in 48 patients who developed NSCLC recurrence.